Lupus kidney disease under the microscope: new study maps patient health in the gulf
NCT ID NCT04971590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 193 people with lupus nephritis (kidney inflammation caused by lupus) in five Gulf countries. Researchers collected information on their symptoms, treatments, and quality of life, but did not test any new medicine. The goal was to better understand the disease and how it affects patients in this region.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
193 people
The number who actually took part.
- Started
-
Sep 2021
- Finished
-
Oct 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants with lupus nephritis as defined by physician per participants hospital records prior to the enrolment visit or at diagnosis.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * More than or equal to 18 years of age * Clinician diagnosed LN participants. * At least one visit to the investigational center during 12 months prior to the baseline visit, recorded in medical documentation. * Literacy in English or Arabic allowing to fully comprehend the written informed consent and study-specific patient reported questionnaires. Exclusion Criteria: * Incomplete medical records to be able to assess the disease severity or absence of any of the following renal laboratory results from the medical record within the last twelve months: a. Urinary protein to creatinine ratio (UPCR) or 24-hour proteinuria or urine sediment (activity). b. Serum creatinine or estimated glomerular filtration rate (eGFR); or measured glomerular filtration rate (GFR), if eGFR is not available. * Current or medical history of: a. Congenital or acquired immunodeficiency. b. Malignancy in active treatment phase. c. Acute viral infection, such as human immunodeficiency virus (HIV) infection, requiring hospitalization.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Systemic lupus erythematosus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Shweikh, Kuwait
-
GSK Investigational Site
Bawshar, Oman
-
GSK Investigational Site
Alrayyan, Qatar
-
GSK Investigational Site
Abu Dhabi, United Arab Emirates
-
GSK Investigational Site
Al Ain City, United Arab Emirates
-
GSK Investigational Site
Dubai, United Arab Emirates
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ear-Zapping device may quiet lupus pain and fatigue
- Can a weekly dipstick at home catch lupus kidney damage early?
- Do rheumatic diseases quietly damage the Eye's oil glands?
- Can a blood test catch lupus flares earlier?
- Can one pill tame four autoimmune diseases? a Long-Term trial puts it to the test
- Can a single drug tame multiple autoimmune diseases?